secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001104659-26-029588
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent to present preclinical data on firmonertinib and ARR-002 at AACR 2026
------------------------------------------------------------------------------

- Firmonertinib preclinical data shows high potency and brain penetrance; supports ongoing Phase 3 in EGFR ex20ins NSCLC.
- ARR-002 (MUC16/NaPi2b ADC) shows superior in vivo efficacy vs single-target ADCs in OVCAR-3 xenograft model.
- ARR-002 demonstrates favorable tolerability in cynomolgus monkeys with reversible hematologic findings.
- ARR-002 also selected for oral presentation at AACR Clinical Research Mini Symposium by Aarvik.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926029588/0001104659-26-029588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926029588/avbp-20260317x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-029588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer